Article
Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO.
Leukemia - 1 Jan 2023
Dumas Pierre-Yves, Raffoux Emmanuel, Bérard Emilie, Bertoli Sarah, Hospital Marie-Anne, Heiblig Maël, Desbrosses Yohann, Bonmati Caroline, Pautas Cécile, Lambert Juliette, Orvain Corentin, Banos Anne, Pasquier Florence, Peterlin Pierre, Marchand Tony, Uzunov Madalina, Frayfer Jamilé, Turlure Pascal, Cluzeau Thomas, Jourdan Eric, Himberlin Chantal, Tavernier Emmanuelle, Villate Alban, Haiat Stephanie, Chretien Marie-Lorraine, Carre Martin, Chantepie Sylvain, Vaida Ioana, Wemeau Mathieu, Chebrek Safia, Guillerm Gaelle, Guièze Romain, Debarri Houria, Gehlkopf Eve, Laribi Kamel, Marcais Ambroise, Santagostino Alberto, Béné Marie-Christine, Mineur Ariane, Pigneux Arnaud, Dombret Hervé, Récher Christian
Abstract excerpt
The real-world efficacy and safety of gilteritinib was assessed in an ambispective study that included 167 R/R FLT3-mutated AML patients. Among them, 140 received gilteritinib as single agent (cohort B), including 67 previously treated by intensive chemotherapy and midostaurin (cohort C). The mai...
Topics
- Humans
- Female
- Mutation
- Leukemia, Myeloid, Acute
- Staurosporine
- fms-Like Tyrosine Kinase 3